Clinical Research Directory

Inclusion Criteria: * History of diagnosis of prostate cancer after undergoing prostatectomy * No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic * Eastern Cooperative Oncology Group (ECOG) performance scale 0-2 * Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable * Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry * PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion * All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients should not have any uncontrolled illness including ongoing or active infection * Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy * Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years * Study-specific exclusions: * History of prior radiation to the pelvis * History of uncontrolled inflammatory bowel disease * Unable to comply with radiation therapy procedures * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study